The Basics
If you’re comparing tirzepatide vs semaglutide, you’re not alone. Both are prescription medications typically taken as a weekly injection. Both may help curb appetite, which can make people feel less hungry and more satisfied after eating.
We’ll keep it easy: the differences, what they might feel like, and what to watch for so that you can decide with a licensed clinician what makes sense for you. Just a heads-up; this is general info, not medical advice. Everyone responds differently.
Who They’re For: Based on FDA Indications
- Weight management (adults): Wegovy® (semaglutide) and Zepbound® (tirzepatide) are indicated for adults with BMI ≥30, or BMI ≥27 with at least one weight-related condition.
- Type 2 diabetes: Ozempic® (semaglutide) and Mounjaro® (tirzepatide) are indicated (with diet and exercise) to improve blood sugar control in people with type 2 diabetes.
- Sleep apnea: Zepbound® is also indicated to treat moderate to severe obstructive sleep apnea in adults with obesity.
How Are They Different?
Both medications affect appetite and blood sugar signaling, but they’re not the same.
Semaglutide
Semaglutide is a GLP-1 receptor agonist.
Here’s what you might notice:
- Feeling fuller sooner
- Thinking about foods less often
- Having an easier time sticking to smaller portions
Tirzepatide
Tirzepatide acts on both GLP-1 and GIP receptors. Like semaglutide, tirzepatide can support appetite control–helping you feel full sooner and making cravings easier to manage.
On average, tirzepatide (as studied in the SURMOUNT trials and later marketed as Zepbound® for weight management and Mounjaro® for type 2 diabetes) tends to come out ahead in studies (about 20-21% vs about 15% in the STEP weight-management trials of semaglutide 2.4 mg [Wegovy®], a separate trial). But everyone’s experience is different, especially when it comes to side effects.
If you’re comparing semaglutide vs tirzepatide for weight management, this “one pathway vs two pathways” difference is usually the simplest place to start.
